<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00596635</url>
  </required_header>
  <id_info>
    <org_study_id>0606001581</org_study_id>
    <secondary_id>DF06-005</secondary_id>
    <nct_id>NCT00596635</nct_id>
  </id_info>
  <brief_title>Cranberry for UTI Prevention in Residents of Long Term Care Facilities</brief_title>
  <acronym>PACS</acronym>
  <official_title>Cranberry for UTI Prevention in Residents of Long Term Care Facilities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Urinary tract infections (UTIs) affect over 7 million men and women per year and cost the
      health care industry over 1 billion dollars annually. The incidence of UTI increases markedly
      in elderly institutionalized persons and leads to excessive antimicrobial usage, emergency
      room visits, hospitalization, sepsis, and death. The use of antimicrobials to prevent UTI in
      elderly nursing home patients is not recommended and is fraught with problems such as adverse
      reactions, drug interactions, and the development of drug-resistant organisms. There is no
      accepted method of preventing UTI in residents of nursing homes, a vulnerable and
      understudied population with significant morbidity from UTI.

      The overall goal of this proposal is to conduct a prospective cohort pilot study that
      evaluates the feasibility of using cranberry to prevent UTI in nursing home residents. Each
      of the aims is critical for the optimal design of a larger placebo-controlled, definitive
      trial of cranberry for prevention of UTI in nursing home residents and will provide the
      essential preliminary data for future larger studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cranberry products represent a novel, non-antimicrobial method for prevention of UTI. There
      is evidence for a plausible mechanism and efficacy for UTI prevention in healthy
      premenopausal women. Limited clinical studies of cranberry products in elderly men and women
      have demonstrated reductions in bacteriuria but have not been of adequate size or quality to
      support the use of cranberry in this population or result in changes in patient care. Thus, a
      properly designed, definitive study demonstrating efficacy of cranberry in preventing UTI in
      this population is needed. However, before a large-scale, placebo-controlled trial can be
      justified, the complexities inherent to studying older nursing home residents need to be
      addressed. These include issues related to collecting uncontaminated urine samples,
      understanding the microbiology of UTI in this population, and devising an acceptable
      intervention regimen. The overall goal of this proposal is to conduct a prospective cohort
      pilot study that evaluates the feasibility of using cranberry to prevent UTI in nursing home
      residents. Each of the aims listed below is critical for the optimal design of a larger
      placebo-controlled, definitive trial of cranberry for prevention of UTI in nursing home
      residents and will provide the essential preliminary data for a future RO1 level grant
      application.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Urine Cultures Collected Out of the Total Number Expected to be Collected.</measure>
    <time_frame>6 months</time_frame>
    <description>Urine cultures were collected at baseline and monthly for six months. The total number of urine cultures collected out of the total number that were expected to be collected are shown.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With E.Coli Isolated From Urine Culture</measure>
    <time_frame>6 months</time_frame>
    <description>Urine cultures were obtained at baseline and monthly for six months. Any participant that had E.coli isolated at least once is listed as meeting the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With &gt;100,000 Colony Forming Units Per Milliliter of Any Organism Isolated From Urine Culture</measure>
    <time_frame>6 months</time_frame>
    <description>Urine cultures were obtained at baseline and monthly for 6 months. If a urine culture had &gt;100,000 colony forming units per milliliter of any organism on any of the urine cultures obtained, the participant is noted as meeting the outcome.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Urinary Tract Infection</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No cranberry capsules administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>One cranberry capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 650mg cranberry capsule daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Two cranberry capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 650 mg cranberry capsule twice daily (bid)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Once Daily Cranberry Capsule</intervention_name>
    <description>650mg capsule pure cranberry powder</description>
    <arm_group_label>One cranberry capsule</arm_group_label>
    <other_name>Theralogix: Theracran cranberry supplement, 650mg capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Twice Daily Cranberry Capsules</intervention_name>
    <description>One 650mg cranberry capsule administered twice per day</description>
    <arm_group_label>Two cranberry capsules</arm_group_label>
    <other_name>Theralogix: Theracran cranberry supplement, 650mg capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Greater than 60 years old and a resident of the nursing home or assisted living
             facility for greater than 30 days duration

        Exclusion Criteria:

          -  Having a known major anatomic abnormality of the urinary tract

          -  Presence of acute UTI symptom

          -  Intolerance or allergy to cranberry products

          -  Current use of cranberry for prevention of UTI

          -  Use of warfarin

          -  History of kidney stones

          -  Presence of a chronic indwelling bladder catheter

          -  Dialysis dependence

          -  Chronic suppressive antibiotics

          -  Immunocompromised state due to hematological malignancies, HIV infection, chronic high
             dose (&gt;10mg daily) prednisone or equivalent steroid use.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manisha Juthani-Mehta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University School of Medicine, Assistant Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School of Medicine, Internal Medicine, Section of Infectious Diseases</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Juthani-Mehta M, Perley L, Chen S, Dziura J, Gupta K. Feasibility of cranberry capsule administration and clean-catch urine collection in long-term care residents. J Am Geriatr Soc. 2010 Oct;58(10):2028-30. doi: 10.1111/j.1532-5415.2010.03080.x.</citation>
    <PMID>20929476</PMID>
  </results_reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2008</study_first_submitted>
  <study_first_submitted_qc>January 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2008</study_first_posted>
  <results_first_submitted>June 30, 2010</results_first_submitted>
  <results_first_submitted_qc>September 1, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 23, 2010</results_first_posted>
  <last_update_submitted>March 19, 2013</last_update_submitted>
  <last_update_submitted_qc>March 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>UTI</keyword>
  <keyword>elderly</keyword>
  <keyword>prevention</keyword>
  <keyword>cranberry</keyword>
  <keyword>E.Coli</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Four dementia units participated in this study. Exclusion criteria included: 1)indwelling catheter, 2)residence &lt;4 weeks, 3)prednisone therapy, 4)active UTI symptoms, 5)terminal, 6)end stage renal disease, 7)&lt;60 years old, 8)chronic suppressive antibiotic therapy, 9)history of kidney stones, 10)unable to provide baseline urine, 11)warfarin therapy.</recruitment_details>
      <pre_assignment_details>If a participant could not provide a baseline urine specimen or met an exclusion criterion prior to group assignment but after consent, he or she was not enrolled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>No Cranberry Capsules</title>
          <description>Control Group No Cranberry Capsule</description>
        </group>
        <group group_id="P2">
          <title>One Cranberry Capsule</title>
          <description>1 650mg cranberry capsule daily</description>
        </group>
        <group group_id="P3">
          <title>2 Cranberry Capsules</title>
          <description>1 650 mg cranberry capsule twice daily (bid)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment for symptomatic UTI</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hip fracture</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Could not provide urine specimen</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>No Cranberry Capsules</title>
          <description>Control Group No Cranberry Capsule</description>
        </group>
        <group group_id="B2">
          <title>One Cranberry Capsule</title>
          <description>1 650mg cranberry capsule daily</description>
        </group>
        <group group_id="B3">
          <title>2 Cranberry Capsules</title>
          <description>1 650 mg cranberry capsule twice daily (bid)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="19"/>
            <count group_id="B4" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85.76" spread="11.76"/>
                    <measurement group_id="B2" value="88.30" spread="6.16"/>
                    <measurement group_id="B3" value="86.68" spread="5.16"/>
                    <measurement group_id="B4" value="86.82" spread="7.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With E.Coli Isolated From Urine Culture</title>
        <description>Urine cultures were obtained at baseline and monthly for six months. Any participant that had E.coli isolated at least once is listed as meeting the outcome.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>No Cranberry Capsules</title>
            <description>Control Group No Cranberry Capsule</description>
          </group>
          <group group_id="O2">
            <title>One Cranberry Capsule</title>
            <description>1 650mg cranberry capsule daily</description>
          </group>
          <group group_id="O3">
            <title>2 Cranberry Capsules</title>
            <description>1 650 mg cranberry capsule twice daily (bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With E.Coli Isolated From Urine Culture</title>
          <description>Urine cultures were obtained at baseline and monthly for six months. Any participant that had E.coli isolated at least once is listed as meeting the outcome.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With &gt;100,000 Colony Forming Units Per Milliliter of Any Organism Isolated From Urine Culture</title>
        <description>Urine cultures were obtained at baseline and monthly for 6 months. If a urine culture had &gt;100,000 colony forming units per milliliter of any organism on any of the urine cultures obtained, the participant is noted as meeting the outcome.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>No Cranberry Capsules</title>
            <description>Control Group No Cranberry Capsule</description>
          </group>
          <group group_id="O2">
            <title>One Cranberry Capsule</title>
            <description>1 650mg cranberry capsule daily</description>
          </group>
          <group group_id="O3">
            <title>2 Cranberry Capsules</title>
            <description>1 650 mg cranberry capsule twice daily (bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With &gt;100,000 Colony Forming Units Per Milliliter of Any Organism Isolated From Urine Culture</title>
          <description>Urine cultures were obtained at baseline and monthly for 6 months. If a urine culture had &gt;100,000 colony forming units per milliliter of any organism on any of the urine cultures obtained, the participant is noted as meeting the outcome.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Urine Cultures Collected Out of the Total Number Expected to be Collected.</title>
        <description>Urine cultures were collected at baseline and monthly for six months. The total number of urine cultures collected out of the total number that were expected to be collected are shown.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>No Cranberry Capsules</title>
            <description>Control Group No Cranberry Capsule</description>
          </group>
          <group group_id="O2">
            <title>One Cranberry Capsule</title>
            <description>1 650mg cranberry capsule daily</description>
          </group>
          <group group_id="O3">
            <title>2 Cranberry Capsules</title>
            <description>1 650 mg cranberry capsule twice daily (bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Urine Cultures Collected Out of the Total Number Expected to be Collected.</title>
          <description>Urine cultures were collected at baseline and monthly for six months. The total number of urine cultures collected out of the total number that were expected to be collected are shown.</description>
          <units>Urine cultures</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of urine cultures expected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of urine cultures collected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>No Cranberry Capsules</title>
          <description>Control Group No Cranberry Capsule</description>
        </group>
        <group group_id="E2">
          <title>One Cranberry Capsule</title>
          <description>1 650mg cranberry capsule daily</description>
        </group>
        <group group_id="E3">
          <title>2 Cranberry Capsules</title>
          <description>1 650 mg cranberry capsule twice daily (bid)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The inability to follow all participants for the full six months reflects the vulnerability of the population.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Manisha Juthani-Mehta, MD</name_or_title>
      <organization>Yale University School of Medicine</organization>
      <phone>(203)785-4140</phone>
      <email>manisha.juthanimehta@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

